Equities analysts predict that Veru Inc (NASDAQ:VERU) will post ($0.09) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Veru’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.09). Veru posted earnings of ($0.10) per share in the same quarter last year, which indicates a positive year over year growth rate of 10%. The business is scheduled to report its next quarterly earnings results on Tuesday, January 1st.

According to Zacks, analysts expect that Veru will report full-year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.38) to ($0.33). For the next year, analysts forecast that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.26) to ($0.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Veru.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). Veru had a negative net margin of 130.26% and a negative return on equity of 38.09%. The company had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $5.20 million.

A number of research analysts have recently commented on the company. HC Wainwright set a $5.00 target price on Veru and gave the company a “buy” rating in a research report on Tuesday, August 28th. Maxim Group reiterated a “buy” rating and set a $10.00 target price on shares of Veru in a research report on Monday, August 27th. Zacks Investment Research downgraded Veru from a “hold” rating to a “sell” rating in a research report on Tuesday, August 21st. ValuEngine upgraded Veru from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Finally, Dawson James reiterated a “buy” rating on shares of Veru in a research report on Monday, June 25th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.83.

Shares of NASDAQ VERU traded up $0.03 during midday trading on Wednesday, reaching $1.97. 976 shares of the stock traded hands, compared to its average volume of 113,324. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.80 and a current ratio of 1.01. The company has a market capitalization of $107.25 million, a P/E ratio of -8.16 and a beta of 0.69. Veru has a one year low of $0.90 and a one year high of $3.00.

A hedge fund recently bought a new stake in Veru stock. ACG Wealth purchased a new position in Veru Inc (NASDAQ:VERU) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 77,000 shares of the company’s stock, valued at approximately $156,000. ACG Wealth owned about 0.14% of Veru as of its most recent SEC filing. 5.20% of the stock is currently owned by hedge funds and other institutional investors.

About Veru

Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Read More: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.